Inactive Instrument

Highlights PRIA ACQU

Equities

PMGM

US74275N1028

Highlights

Unlock all the news: Be the first to know and act before the market!

AEON Biopharma Completes Business Combination With Priveterra Acquisition; Shares Slump	23-07-24	MT
Priveterra Acquisition Completes Merger With AEON Biopharma	23-07-21	MT
Priveterra Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	23-07-20	CI
Priveterra Acquisition Gets New York Stock Exchange Approval for Listing of AEON Biopharma Stock, Warrants	23-07-18	MT
Priveterra Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
PRIVETERRA ACQUISITION CORP. - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations	23-04-10	AQ
PRIVETERRA ACQUISITION CORP. - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations	23-04-05	AQ
Priveterra Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22	CI
PRIVETERRA ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-02-22	AQ
PRIVETERRA ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-06	AQ
AEON Biopharma and Priveterra Acquisition Corp. Announce Filing of S-4 Registration Statement for Proposed Business Combination	22-12-27	BU
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine	22-12-21	AQ
Priveterra Acquisition : Business Combination Agreement - Form 8-K	22-12-13	PU
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.	22-12-12	CI
Priveterra Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
PRIVETERRA ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-14	AQ
PRIVETERRA ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-12	AQ
Priveterra Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
PRIVETERRA ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PRIA ACQU

Equities

PMGM

US74275N1028

Highlights

Filters